Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Interest & Investment Income: 2020-2024

Historic Interest & Investment Income for UroGen Pharma (URGN) over the last 5 years, with Dec 2024 value amounting to $8.7 million.

  • UroGen Pharma's Interest & Investment Income fell 62.33% to $979,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year decrease of 4.26%. This contributed to the annual value of $8.7 million for FY2024, which is 149.27% up from last year.
  • Latest data reveals that UroGen Pharma reported Interest & Investment Income of $8.7 million as of FY2024, which was up 149.27% from $3.5 million recorded in FY2023.
  • In the past 5 years, UroGen Pharma's Interest & Investment Income registered a high of $8.7 million during FY2024, and its lowest value of $365,000 during FY2021.
  • Over the past 3 years, UroGen Pharma's median Interest & Investment Income value was $3.5 million (recorded in 2023), while the average stood at $4.4 million.
  • As far as peak fluctuations go, UroGen Pharma's Interest & Investment Income tumbled by 81.62% in 2021, and later spiked by 244.46% in 2023.
  • Yearly analysis of 5 years shows UroGen Pharma's Interest & Investment Income stood at $2.0 million in 2020, then crashed by 81.62% to $365,000 in 2021, then spiked by 176.71% to $1.0 million in 2022, then skyrocketed by 244.46% to $3.5 million in 2023, then skyrocketed by 149.27% to $8.7 million in 2024.